Evaluation of the efficacy of combined targeted therapy with trametinib and dabrafenib

Trametinib and dabrafenib (Dabrafenib) are MEK inhibitors and BRAF inhibitors respectively. The purpose of their combined use is to more effectively inhibit the MAPK signaling pathway, thereby achieving double blockade of BRAF V600 mutation-positive tumor cells. This combination has clinically become the first-line recommended regimen for unresectable or metastatic BRAF V600E/K-mutated melanoma, BRAF V600E-mutated non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC).

According to the analysis of international clinical research data, combination therapy significantly prolonged the progression-free survival (PFS) and overall survival (OS) of patients compared with monotherapy, and showed a higher objective response rate (ORR) in multiple key trials. The advantage of its mechanism is that although the BRAF inhibitor alone has a rapid onset of action, it is easy to develop drug resistance due to the reactivation of the downstream MEK pathway; while the combination of MEK inhibitors can block the drug resistance mechanism, reduce the escape of tumor cells, and improve the persistence of treatment.

In terms of safety, the side effect spectrum of combination medication is similar to that of single medication, but the incidence of some adverse reactions, such as rash, fever, impact on cardiac function, and retinopathy, is slightly increased and requires regular monitoring and management. Clinical experience shows that reasonable dose adjustment and supportive treatment can enable most patients to continue to maintain effective treatment.

Real-world experience also confirms that this combination can quickly reduce tumor burden, improve symptoms, and achieve long-term disease control in some patients. Especially in high-risk subgroups such as brain metastasis and liver metastasis, the survival benefit of the combined regimen is still significant.

In general, the combined targeted therapy of dabrafenib and trametinib has established an important position in a variety of BRAF mutation-related cancers and has become one of the important recommendations in global clinical guidelines.

Reference materials:https://go.drugbank.com/drugs/DB08911